agilon Health Advances Proactive, Patient-Centered Heart Failure Care Through Clinical Pathway
For more than a decade, value-based care has been built around a straightforward but ambitious idea: healthcare should focus on improving patient outcomes and delivering meaningful value rather than rewarding volume alone.
Although the principle has gained broad acceptance across the healthcare industry, putting it into practice remains a significant challenge. Healthcare organizations must identify interventions that can improve clinical outcomes, enhance the patient experience, reduce avoidable complications, and prevent hospitalizations that contribute significantly to overall healthcare spending.
That challenge has become increasingly important as more Americans enter Medicare with complex and often overlapping health needs. Medical advances have improved the ability to diagnose and treat many diseases, but many patients still experience preventable complications, delayed diagnoses, and worsening chronic conditions. At the same time, healthcare spending continues to grow faster than the broader economy.
agilon health believes clinical pathways can help address this gap by connecting evidence-based recommendations with the realities of everyday primary care.
The company’s approach focuses on translating clinical evidence into practical interventions that can be integrated into physicians’ workflows. By combining data intelligence, artificial intelligence, clinical expertise, and physician-patient relationships, agilon aims to help identify disease earlier and support more timely treatment.
The company focuses on conditions that have a disproportionate impact on patients, healthcare utilization, and spending, including heart failure, dementia, chronic obstructive pulmonary disease (COPD), diabetes, and chronic kidney disease.
Heart failure represents one of the clearest examples of how a proactive clinical pathway can potentially change the trajectory of disease.
Moving Heart Failure Care Earlier in the Patient Journey
Heart failure is one of the most serious chronic conditions affecting older adults. The disease can lead to frequent hospitalizations, reduced quality of life, functional decline, and increased mortality.
One of the challenges associated with heart failure is that the disease can progress significantly before it is formally diagnosed. Many patients may experience symptoms for months or years before receiving a diagnosis, while others may first be diagnosed during an emergency department visit or hospitalization.
According to agilon, approximately 38% of new heart failure cases in the United States are diagnosed in an acute care setting after patients have already progressed to severe symptoms or a clinical crisis.
This creates a significant opportunity for earlier detection and intervention.
If patients at risk of heart failure can be identified earlier, physicians may be able to begin evidence-based treatment before the disease progresses to more advanced stages.
The STOP-HF trial provided evidence supporting the potential value of screening individuals at risk for heart failure and providing appropriate follow-up care. The findings showed that early identification and management could help reduce disease progression and cardiovascular hospitalizations.
However, screening alone is not enough.
As agilon expanded screening programs across partner practices, the organization found that nearly half of patients with newly identified heart failure were already experiencing symptoms.
These patients were already living with the disease. The challenge was that the condition had not yet been recognized.
The experience reinforced an important lesson: improving outcomes requires healthcare systems to identify patients earlier and connect them with effective treatment as quickly as possible.
From Diagnosis to Evidence-Based Treatment
A diagnosis is only the beginning of the care journey.
Although identifying disease earlier is important, diagnosis alone does not necessarily improve outcomes. Patients benefit when diagnosis is followed by timely treatment, ongoing monitoring, medication management, and support for overcoming barriers to care.
Heart failure is a strong example of this challenge.
Clinical evidence has demonstrated that guideline-directed medical therapies can reduce hospitalizations, improve symptoms, and extend survival for many patients with heart failure. However, a significant number of eligible patients do not receive the full range of recommended therapies.
There can be many reasons for this gap. Patients may face medication affordability challenges, difficulties managing multiple prescriptions, side effects, or challenges attending frequent appointments. Physicians may also have limited time to monitor therapy and make repeated adjustments within traditional care models.
To help address these challenges, agilon developed a heart failure clinical pathway supported by a virtual pharmacy program.
The pathway is designed to help physicians identify patients earlier and support treatment decisions. The virtual pharmacy team works alongside primary care physicians and patients to help optimize medications, monitor treatment response, address affordability and access barriers, and reinforce adherence.
The objective is not simply to prescribe appropriate medications. The broader goal is to help patients start recommended therapies, remain on treatment, and receive the full potential benefit of medications proven to improve outcomes.
Improving the Timing of Heart Failure Diagnosis
The results from patients enrolled in the virtual pharmacy program, including individuals in Medicare Advantage and Accountable Care Organization populations, demonstrated significant changes in care patterns.
One of the most notable results involved the setting in which heart failure diagnoses occurred.
The percentage of heart failure diagnoses occurring during hospitalization fell from a baseline of approximately 15% to 20% to around 5%.
This shift suggests that more patients were being identified before reaching a severe clinical crisis requiring hospitalization.
Earlier diagnosis can create additional opportunities for intervention. Instead of waiting until patients experience severe symptoms, physicians may be able to initiate treatment and monitor patients while they remain in lower-acuity settings.
For patients, this can mean avoiding some of the disruption and risks associated with hospitalization.
It can also provide more time for physicians and patients to work together on a long-term care plan.
Increasing Use of Guideline-Directed Therapies
Another area of progress involved the use of recommended medications.
Among symptomatic patients with heart failure with preserved ejection fraction, the use of SGLT2 inhibitors increased from approximately 25% to approximately 65%.
SGLT2 inhibitors have become an important component of heart failure management and are associated with reductions in heart failure-related hospitalizations for appropriate patients.
The increase in utilization demonstrates how structured clinical pathways and ongoing medication support can help close gaps between evidence-based recommendations and actual treatment.
The program also produced changes among patients with heart failure with reduced ejection fraction.
On average, patients increased from receiving approximately two pillars of guideline-directed medical therapy to three.
According to agilon, nationally only about one in four eligible patients receive triple therapy.
Approximately half of program graduates with reduced ejection fraction were receiving all four recommended pillars of therapy at maximally tolerated doses.
These changes are significant because heart failure treatment often requires ongoing adjustments. Patients may need medications to be introduced gradually, doses to be adjusted, and treatment plans to be modified based on tolerance, kidney function, blood pressure, symptoms, and other clinical factors.
The process can require sustained follow-up rather than a single clinical decision.
Combining Technology With Clinical Judgment
agilon’s approach relies on the use of data and artificial intelligence to help physicians develop a more complete and timely understanding of each patient.
Healthcare information is often distributed across multiple systems. A patient’s clinical history, medications, laboratory results, hospital encounters, claims information, and other data may exist in different locations.
agilon’s platform is designed to bring information from disparate sources together to create a more comprehensive clinical picture.
AI-powered tools can then help translate this information into actionable insights that can be integrated into physicians’ existing workflows.
The objective is not to replace clinical judgment.
Instead, technology is used to help physicians identify patients who may require attention, recognize patterns, and receive information that can support treatment decisions.
The physician-patient relationship remains central to the care model.
Technology can help identify opportunities, but clinical professionals remain responsible for evaluating patients and making decisions based on individual circumstances.
Supporting Patients Beyond the Clinic
The virtual pharmacy program also reflects a broader shift in how chronic disease management is delivered.
Patients with heart failure may require frequent medication adjustments and ongoing monitoring. Traditional care models may require patients to make repeated trips to a clinic for routine follow-up.
Virtual pharmacy services can provide another layer of support.
Patients can receive medication management assistance remotely, helping them address questions, overcome barriers to access, and remain engaged with their treatment plans.
This can be particularly valuable for older adults who may face transportation challenges or other barriers to frequent in-person visits.
Remote support can also help make chronic disease management more continuous.
Instead of relying only on periodic visits, care teams can provide ongoing assistance as patients begin and adjust treatment.
The goal is to make care more accessible while helping patients remain engaged with therapies that can improve their health.
A Broader Model for Chronic Disease Management
Heart failure has become an example of what agilon believes can be achieved through a coordinated clinical pathway.
The company is now applying lessons from its heart failure program to other high-impact chronic conditions.
These include dementia, COPD, diabetes, and chronic kidney disease.
Each of these conditions presents unique clinical challenges, but they share several characteristics. They can progress over time, often require ongoing management, and can lead to significant healthcare utilization when diagnosis or treatment is delayed.
Clinical pathways can help establish more consistent approaches to identifying patients, evaluating risk, supporting treatment, and monitoring outcomes.
For physicians, this can provide greater visibility into patient populations and additional clinical support.
For patients, the objective is to improve the opportunity to maintain health, function, and independence.
Aligning Better Outcomes With Lower Costs
One of the central challenges in healthcare is the perceived tension between improving outcomes and reducing spending.
However, many of the interventions that improve patient health can also reduce the need for costly acute care.
For example, earlier identification of heart failure may allow physicians to begin treatment before the disease progresses to a crisis. Better medication management may help reduce avoidable hospitalizations. Ongoing support may help patients remain adherent to therapies that improve long-term outcomes.
These interventions can benefit patients while potentially reducing costs associated with emergency care and hospital admissions.
This is a central principle of value-based care.
The goal is not to reduce care. Instead, the objective is to provide the right care at the right time and in the right setting.
A clinical pathway can help healthcare organizations move away from a reactive model in which patients receive treatment primarily after complications occur.
Instead, the focus shifts toward prevention, early detection, proactive treatment, and continuous support.
The Future of Proactive, Patient-Centered Care
The experience with heart failure demonstrates the potential of combining clinical pathways, data intelligence, artificial intelligence, and human expertise.
The approach is designed to help healthcare providers identify patients earlier, support evidence-based treatment, and monitor progress over time.
The results from agilon’s heart failure program suggest that meaningful improvements can be achieved across multiple markets and physician groups.
The significance of these results extends beyond the specific metrics.
For patients, earlier diagnosis and improved treatment may mean fewer hospitalizations, better symptom management, improved quality of life, and more time living independently.
For physicians, clinical intelligence and additional support can help make it easier to identify care gaps and manage complex chronic conditions.
For healthcare organizations, proactive interventions may help improve outcomes while reducing the costs associated with preventable complications.
As the healthcare system continues to shift toward value-based models, the ability to execute effectively will become increasingly important.
Clinical pathways may represent one tool for translating evidence into practical care.
By combining data, AI-powered insights, clinical expertise, and trusted physician-patient relationships, healthcare organizations can develop more proactive approaches to chronic disease management.
agilon health’s heart failure pathway demonstrates how such a model can be applied in practice.
The broader opportunity is to build on these lessons and apply them across other conditions that significantly affect patients and healthcare systems.
As the industry continues to seek ways to improve outcomes while managing costs, proactive and patient-centered care models may become increasingly important.
The future of value-based care may ultimately depend on the ability to identify disease earlier, intervene sooner, support patients consistently, and ensure that evidence-based treatment reaches the people who need it.
For heart failure patients, that approach can help change the course of disease. For the broader healthcare system, it may offer a practical model for delivering better outcomes while creating greater value for patients, physicians, and communities.
Source link: https://www.agilonhealth.com/
